Eledon Pharmaceuticals, Inc. (ELDN)

Market Cap	49.61M
Revenue (ttm)	n/a
Net Income (ttm)	-40.33M
Shares Out	24.20M
EPS (ttm)	-1.64
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,294
Open	2.050
Previous Close	2.020
Day's Range	2.020 - 2.080
52-Week Range	1.070 - 2.950
Beta	0.93
Analysts	Strong Buy
Price Target	10.67 (+428.22%)
Earnings Date	May 9, 2024

About ELDN

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: ELDN

Analyst Forecast

According to 3 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price forecast is $10.67, which is an increase of 428.22% from the latest price.

Price Target

$10.67

(428.22% upside)

Analyst Consensus: Strong Buy